Contractile responses to selective phosphodiesterase inhibitors following chronic β-adrenoreceptor activation

Pflugers Archiv European Journal of Physiology

Volumn 452, Issue 2, 2006, Pages 155-163

  Osadchii, Oleg E ^a   Woodiwiss, Angela J ^a   Norton, Gavin R ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

cAMP; Cardiac hypertrophy; Contractile responses; Isoproterenol; Phosphodiesterase inhibitors

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ADRENERGIC BETA-AGONISTS; ANIMALS; CALCIUM; CYCLIC AMP; HEART; ISOPROTERENOL; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NOREPINEPHRINE; ORGAN SIZE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 33745854482     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-005-0025-6     Document Type: Article

References (36)

1. Aquila LA, McCarthy PM, Smedira NG, Young JB, Moravec CS (2004) Cytoskeletal structure and recovery in single human cardiac myocytes. J Heart Lung Transplant 23:954-963
2. Badenhorst D, Veliotes D, Maseko M, Tsotetsi OJ, Brooksbank RL, Naidoo A, Woodiwiss AJ, Norton GR (2003) β-adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension 41:499-504
3. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA (1989) Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65:657-670
4. Bohm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (1988) Subsensitivity of the failing human heart to isoprenaline and milrinone is related to β-adrenoceptor down-regulation. J Cardiovasc Pharmacol 12:726-732
5. Bohm M, Deutsch HJ, Hartmann D, Rosee KL, Stablein A (1997) Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 30:992-996
6. Boknik P, Fockenbrock M, Herzig S, Knapp J, Linck B, Luss H, Muller FU, Muller T, Schmitz W, Schroder F, Neumann J (2000) Protein phosphatase activity is increased in a rat model of long-term β-adrenergic stimulation. Naunyn Schmiedebergs Arch Pharmacol 362:222-231
7. Bristow MR (2000) What type of beta-blocker should be used to treat chronic heart failure? Circulation 102:484-486
8. Collins P, Billings CG, Barer GR, Daly JJ, Jolly A (1975) Quantitation of isoprenaline-induced changes in the ventricular myocardium. Cardiovasc Res 9:797-806
9. Dalla Libera L, Ravara B, Gobbo V, Danieli Betto D, Germinario E, Angelini A, Vescovo G (2005) Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol 38:803-807
10. Feldman MD, Copela L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75:331-339
11. Ganhao MF, Hattingh J, Hurwitz ML, Pitts NI (1991) Evaluation of a simple plasma catecholamine extraction procedure prior to high-performance liquid chromatography and electrochemical detection. J Chromatogr 564:55-66
12. Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN (1996) Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am J Physiol 270:H1159-H1164
13. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA (1986) Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29:506-514
14. Konstam MA, Cody RJ (1995) Short-term use of intravenous milrinone for heart failure. Am J Cardiol 75:822-826
15. Kubalova Z, Terentyev D, Viatchenko-Karpinski S, Nishijima Y, Gyorke I, Terentyeva R, da Cunha DN, Sridhar A, Feldman DS, Hamlin RL, Cames CA, Gyorke S (2005) Abnormal intrastore calcium signaling in chronic heart failure. Proc Natl Acad Sci U S A 102:14104-14109
16. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ (1999) Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 33:924-931
17. Masunaga R, Nagasaka A, Sawai Y, Hayakawa N, Nakai A, Hotta K, Kato Y, Hishida H, Takahashi H, Naka M, Shimada Y, Tanaka T, Hidaka H, Itoh M (2004) Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters. J Mol Cell Cardiol 37:767-774
18. McMartin L, Summers RJ (1999) Functional analysis of desensitization of the β-adrenoceptor signaling pathway in rat cardiac tissues following chronic isoprenaline infusion. Br J Pharmacol 127:1012-1020
19. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Cas LD (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. J Am Coll Cardiol 40:1248-1258
20. Muneyama K, Bauer RJ, Shuman DA, Robins RK, Simon LN (1971) Chemical synthesis and biological activity of 8-substituted adenosine 3′,5′-cyclic monophosphate derivatives. Biochemistry 10:2390-2395
21. 2a receptor activation in rat heart. Am J Physiol 276:H341-H349
22. Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, Meyer TE (2002) Heart failure in pressure overload hypertrophy: the relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 39:664-671
23. Osadchii O, Norton G, Woodiwiss A (2005) Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol 514:201-208
24. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, Pitzus AE, Garcia EH, Obregon R, Brizuela M, Barbagelata A (2004) Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110:2376-2382
25. Sahn DJ, De Maria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation of M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072-1083
26. Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. J Biol Chem 271:16526-16534
27. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR (1998) Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 31:1336-1340
28. Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, Ding JZ, Moggio RA, Hintze TH (1997) Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96:3116-3123
29. Sugden PH, Bogoyevitch MA (1995) Intracellular signaling through protein kinases in the heart. Cardiovasc Res 30:478-492
30. Tse J, Brackett NL, Kuo JF (1978) Alterations in activities of cyclic nucleotide systems and in β-adrenergic receptor-mediated activation of cyclic AMP-dependent protein kinase during progression and regression of isoproterenol-induced cardiac hypertrophy. Biochim Biophys Acta 542:399-411
31. Van der Velden J, Merkus D, Klarenbeek BR, James AT, Boontje NM, Dekkers DHW, Stienen GJM, Lamers JMJ, Duncker DJ (2004). Alterations in myofilament function contribute to left ventricular dysfunction in pigs early after myocardial infarction. Circ Res 95:e85-e95
32. Veliotes DG, Woodiwiss AJ, Deftereos DA, Gray D, Osadchii O, Norton GR (2005) Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adreno-receptor activation. Hypertension 45:914-920
33. Von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Doring V, Kalmar P, Haverich A (1991) Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol 344:90-100
34. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR (2001) Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 103:155-160
35. Wynne DG, Poole-Wilson PA, Harding SE (1993). Incomplete reversal of β-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 109:1071-1078
36. 2+ release. J Pharmacol Exp Ther 310:761-773